Figure 7B shows that co-treatment with mitoxantrone and rapamycin significantly decreased cell viability, as compared with treatment with rapamycin alone, indicating that mitoxantrone sensitizes breast cancer cells to mTOR inhibitors treatment. Here, MTOR is linked to breast carcinoma.